title: Membranous glomerulonephritis, psoriasis and etanercept. A chance or causal association?
abstract: Psoriasis is a cutaneous disease with systemic involvement. Tissue damage is considered to be immune-mediated, and etanercept currently provides effective treatment. Kidney injury arising from this condition has not yet been fully explained in the literature. We present a case of membranous nephropathy with C1q deposits followed by development of psoriasis. In this article we will review the possible association between these conditions and the response to this biological molecule.
authors.affiliation: Hospital Clínico San Carlos, Madrid, Spain. kiqueflorit@hotmail.com
authors.forename: Enrique A
authors.initials: EA
authors.lastname: Florit
authors.forename: Isabel
authors.initials: I
authors.lastname: Ubeda-Aranda
authors.forename: Pablo
authors.initials: P
authors.lastname: Delgado-Conde
authors.forename: Beatriz
authors.initials: B
authors.lastname: Rodríguez-Cubillo
authors.forename: Tania
authors.initials: T
authors.lastname: Monzón-Vázquez
authors.forename: José C
authors.initials: JC
authors.lastname: de la Flor Merino
authors.forename: Francisco
authors.initials: F
authors.lastname: Valga-Amado
authors.forename: Alberto
authors.initials: A
authors.lastname: Barrientos-Guzmán
mesh_terms: D000328:Adult; D000068800:Etanercept; D015433:Glomerulonephritis, Membranous / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D011565:Psoriasis / Q000188:drug therapy* / Q000209:etiology*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*
chemical_list: D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept